Quarterly Results Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Dec'23
Net Sales
160.19
182.56
145.83
174.76
203.80
186.94
177.23
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
160.19
182.56
145.83
174.76
203.80
186.94
177.23
Raw Material Cost
95.42
77.90
98.94
76.50
88.73
76.29
88.41
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
2.53
2.04
2.70
2.15
2.22
1.56
0.94
Selling and Distribution Expenses
58.83
52.28
46.61
46.42
48.58
42.93
50.48
Other Expenses
1.48
1.12
2.01
1.83
1.84
1.34
1.10
Total Expenditure (Excl Depreciation)
171.58
143.37
168.37
143.36
157.91
134.15
150.81
Operating Profit (PBDIT) excl Other Income
-11.399999999999999
39.2
-22.5
31.400000000000002
45.9
52.800000000000004
26.400000000000002
Other Income
2.58
0.78
2.39
4.74
2.95
1.96
6.09
Operating Profit (PBDIT)
8.63
56.10
-8.65
51.44
60.31
66.08
32.12
Interest
2.53
2.04
2.70
2.15
2.22
1.56
0.94
Exceptional Items
-0.34
0.43
-0.03
-0.17
-1.26
1.56
-1.09
Gross Profit (PBDT)
64.77
104.66
46.89
98.27
115.07
110.64
88.82
Depreciation
16.76
16.76
15.45
15.45
12.08
12.08
10.04
Profit Before Tax
-11.00
37.73
-26.83
33.67
44.74
53.99
20.06
Tax
-12.22
7.04
-18.85
7.29
8.53
11.56
3.81
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
5.54
31.55
-8.12
30.59
40.28
45.47
18.38
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
5.54
31.55
-8.12
30.59
40.28
45.47
18.38
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
-4.32
-0.85
0.14
-4.21
-4.07
-3.04
-2.14
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
1.22
30.69
-7.98
26.37
36.22
42.43
16.24
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
1,739.35
1,798.41
1,767.06
1,774.90
1,748.79
1,835.56
1,789.98
Earnings per share (EPS)
0.01
0.07
-0.02
0.07
0.1
0.11
0.04
Diluted Earnings per share
0.01
0.07
-0.02
0.07
0.1
0.11
0.04
Operating Profit Margin (Excl OI)
-6.69%
21.12%
-18.17%
17.88%
22.21%
27.84%
9.03%
Gross Profit Margin
3.6%
29.85%
-7.8%
28.11%
27.88%
35.35%
16.98%
PAT Margin
3.46%
17.28%
-5.57%
17.5%
19.76%
24.32%
10.37%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Jun 2025 is -21.39% vs -2.53% in Jun 2024
Consolidate Net Profit
YoY Growth in quarter ended Jun 2025 is -96.69% vs -34.77% in Jun 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Jun 2025 is -89.55% vs -19.94% in Jun 2024
Interest
YoY Growth in quarter ended Jun 2025 is 13.64% vs 1,000.00% in Jun 2024
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Jun 2025 has fallen from Jun 2024
Compare Quarterly Results Of Guangdong Taienkang Pharmaceutical Co., Ltd. With
Figures in Million
Consolidate Quarterly Results
Change(CNY)
Change(%)
Net Sales
160.19
0
160.19
Other Operating Income
0.00
0.00
0.00
Total Operating income
160.19
0
160.19
Raw Material Cost
95.42
0
95.42
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
2.53
0
2.53
Selling and Distribution Expenses
58.83
0
58.83
Other Expenses
1.48
0.00
1.48
Total Expenditure (Excl Depreciation)
171.58
0
171.58
Operating Profit (PBDIT) excl Other Income
-11.39
0.00
-11.39
Other Income
2.58
0
2.58
Operating Profit (PBDIT)
8.63
0
8.63
Interest
2.53
0
2.53
Exceptional Items
-0.34
0
-0.34
Gross Profit (PBDT)
64.77
0
64.77
Depreciation
16.76
0
16.76
Profit Before Tax
-11.00
0
-11.00
Tax
-12.22
0
-12.22
Provisions and contingencies
0
0
0.00
Profit After Tax
5.54
0
5.54
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
5.54
0
5.54
Share in Profit of Associates
0
0
0.00
Minority Interest
-4.32
0
-4.32
Other related items
0.00
0.00
0.00
Consolidated Net Profit
1.22
0
1.22
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
1,739.35
0
1,739.35
Earnings per share (EPS)
0.01
0
0.01
Diluted Earnings per share
0.01
0
0.01
Operating Profit Margin (Excl OI)
-6.69%
0%
0.00
-6.69%
Gross Profit Margin
3.60%
0%
0.00
3.60%
PAT Margin
3.46%
0%
0.00
3.46%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 16.02 Million
in Jun 2025Figures in Million
QoQ Growth in quarter ended Jun 2025 is -12.27% vs 25.24% in Mar 2025
YoY Growth in quarter ended Jun 2025 is -21.39% vs -2.53% in Jun 2024
Quarterly - Consolidate Net Profit
Consolidate Net Profit 0.12 Million
in Jun 2025Figures in Million
QoQ Growth in quarter ended Jun 2025 is -96.09% vs 483.75% in Mar 2025
YoY Growth in quarter ended Jun 2025 is -96.69% vs -34.77% in Jun 2024
Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 0.60 Million
in Jun 2025Figures in Million
QoQ Growth in quarter ended Jun 2025 is -89.15% vs 602.73% in Mar 2025
YoY Growth in quarter ended Jun 2025 is -89.55% vs -19.94% in Jun 2024
Quarterly - Interest
Interest 0.25 Million
in Jun 2025Figures in Million
QoQ Growth in quarter ended Jun 2025 is 25.00% vs -25.93% in Mar 2025
YoY Growth in quarter ended Jun 2025 is 13.64% vs 1,000.00% in Jun 2024
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) -6.69%
in Jun 2025Figures in %
QoQ Growth in quarter ended Jun 2025 has fallen from Mar 2025
YoY Growth in quarter ended Jun 2025 has fallen from Jun 2024
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
